Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-04-12 pm EDT 5-day change 1st Jan Change
48.28 USD -1.71% Intraday chart for Bristol-Myers Squibb Company -5.92% -5.91%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Jefferies Cuts Bristol-Myers Squibb's Price Target to $56 From $58 MT
TORL BioTherapeutics LLC announced that it has received $158 million in funding from a group of investors CI
Bristol Myers: cancer treatment results CF
Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $40 From $41, Keeps Underweight Rating MT
Bristol Myers Squibb Announces KRAZATI in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer CI
Global markets live: Boeing, Shell, AstraZeneca, Tesla, Meta... Our Logo
Bristol Myers: new data on schizophrenia CF
Bristol Myers' schizophrenia drug reduces symptoms without weight gain in late-stage studies RE
Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication MT
Bristol Myers, 2seventy Get FDA OK for Earlier Abecma Use in Multiple Myeloma DJ
Bristol Myers: FDA approves Abecma in multiple myeloma CF
US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer RE
U.S. FDA allows expanded use of Bristol Myers' cell therapy RE
U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio?S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy CI
Sector Update: Health Care Stocks Lean Higher Pre-Bell Thursday MT
Standard BioTools Enters Into Multi-Year Medicine Research Engagement With Bristol-Myers Squibb MT
Bristol-Myers' Reblozyl Approved in EU as First-Line Treatment of Transfusion-Dependent Anemia MT
Bristol Myers: EU approval extended for Reblozyl CF
European Commission Expands Approval of Bristol Myers Squibb?S Reblozyl® (Luspatercept) CI
Obsidian Therapeutics, Inc. announced that it has received $160.5 million in funding from a group of investors CI
US takes next step in Medicare drug price negotiations with pharma companies RE
Bristol-Myers Squibb Therapy for Pretreated Non-Small Cell Lung Cancer Meets Primary Endpoint MT
Bristol-Myers Solicits Proxies from the Shareholders CI
Bristol-Myers Solicits Proxies from the Shareholders CI
Bristol Myers Squibb Drug Misses Endpoint in Crohn's Disease Trial DJ
Chart Bristol-Myers Squibb Company
More charts
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
27
Last Close Price
49.12 USD
Average target price
56.28 USD
Spread / Average Target
+14.58%
Consensus
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. News Bristol-Myers Squibb Company
  5. Aurora Cannabis Names Simona King CFO; Completes Share Consolidation